<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00270816</url>
  </required_header>
  <id_info>
    <org_study_id>NEU - CYC - 06</org_study_id>
    <nct_id>NCT00270816</nct_id>
  </id_info>
  <brief_title>Interferon ß-1b Treatment by Cyclical Administration</brief_title>
  <official_title>Effect of Cyclical Administration of Interferon β-1b in Multiple Sclerosis - Comparison With Normal Dose.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>S. Andrea Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Italian Multiple Sclerosis Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>S. Andrea Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The therapy with Interferon-ß-1b reduces the inflammatory component of multiple sclerosis
      with positive effects on the disease course. The 8 MUI dose at alternate days is kept
      constant for years. About 1/3 of patients suspend treatment by three years due to side
      effects or suspected or accepted ineffectiveness. The main objective of the study is to
      verify the safety and effectiveness of a cyclical administration (a month of suspension after
      two of treatment) from the beginning of treatment. There is the possibility that a scheme
      envisaging therapy free intervals can reduce the onset of negative feedbacks (antagonising
      the drug therapeutic effect) compared to the standard administration protocol. This might
      also result in an increase of the drug effectiveness and/or in a longer duration of
      effectiveness itself. Finally, cyclical administration allows patients to spend actual
      periods of &quot;therapeutic vacation&quot;, with positive psychological effects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2005</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of lesions in T1 and new lesions in T2</measure>
    <time_frame>baseline and after 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>number of gad-enhancing lesions in T1</measure>
    <time_frame>baseline and after 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>relapse rate</measure>
    <time_frame>baseline and after 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>volume of T1 lesions (black holes)</measure>
    <time_frame>baseline and after 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>interferon beta cyclical administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interferon ß-1b Treatment by Cyclical Administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Interferon ß-1b Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Interferon ß-1b Treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon-ß-1b</intervention_name>
    <description>250 micrograms (8 MIU) administered subcutaneously (sc) every other day with a discontinuance month every 2 months</description>
    <arm_group_label>interferon beta cyclical administration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon ß-1b</intervention_name>
    <description>250 micrograms (8 MIU) administered subcutaneously (sc) every other day</description>
    <arm_group_label>Interferon ß-1b Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients affected by remitting Multiple Sclerosis who had at least a relapse in the
             last year of the disease.

          -  Satisfying general clinical conditions according to the researcher. Adequate hepatic
             function. Capacity to use adequate contraceptive techniques during the study.

        Exclusion Criteria:

          -  Any other disease that might better explain signs and symptoms of the patient.

          -  Any other disability condition that might interfere with the clinical evolution.

          -  History of hypersensitivity to natural or recombinant interferon or to human albumin.

          -  Clinically significant heart diseases and not controlled like dysrhythmias, angina
             pectoris or congestive heart failure.

          -  Not adequately controlled epilepsy.

          -  Inability, according to the examining commission, to grant a complete compliance with
             the protocol requirements for the whole study.

          -  Previous therapies modifying the disease course in the last six months.

          -  Steroid therapies in the last 3 months.

          -  Pregnancy, lactation, serological positivity to the pregnancy test during the
             screening period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Salvetti, MD</last_name>
    <role>Study Director</role>
    <affiliation>S.Andrea Hospital, University of Rome &quot;La Sapienza&quot;</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Azienda Ospedaliera S. Andrea, II Facoltà di Medicina e Chirurgia, Università di Roma &quot;La Sapienza&quot;</name>
      <address>
        <city>Rome</city>
        <zip>00139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.ospedalesantandrea.it</url>
    <description>SPONSOR SITE</description>
  </link>
  <reference>
    <citation>Steinman L. Immunotherapy of multiple sclerosis: the end of the beginning. Curr Opin Immunol. 2001 Oct;13(5):597-600. Review.</citation>
    <PMID>11544011</PMID>
  </reference>
  <reference>
    <citation>Calabresi PA, Stone LA, Bash CN, Frank JA, McFarland HF. Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI. Neurology. 1997 May;48(5):1446-8.</citation>
    <PMID>9153489</PMID>
  </reference>
  <reference>
    <citation>Richert ND, Zierak MC, Bash CN, Lewis BK, McFarland HF, Frank JA. MRI and clinical activity in MS patients after terminating treatment with interferon beta-1b. Mult Scler. 2000 Apr;6(2):86-90.</citation>
    <PMID>10773853</PMID>
  </reference>
  <reference>
    <citation>Langenkamp A, Messi M, Lanzavecchia A, Sallusto F. Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat Immunol. 2000 Oct;1(4):311-6.</citation>
    <PMID>11017102</PMID>
  </reference>
  <reference>
    <citation>Rissoan MC, Soumelis V, Kadowaki N, Grouard G, Briere F, de Waal Malefyt R, Liu YJ. Reciprocal control of T helper cell and dendritic cell differentiation. Science. 1999 Feb 19;283(5405):1183-6.</citation>
    <PMID>10024247</PMID>
  </reference>
  <reference>
    <citation>Skok J, Poudrier J, Gray D. Dendritic cell-derived IL-12 promotes B cell induction of Th2 differentiation: a feedback regulation of Th1 development. J Immunol. 1999 Oct 15;163(8):4284-91.</citation>
    <PMID>10510367</PMID>
  </reference>
  <reference>
    <citation>McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001 Jul;50(1):121-7.</citation>
    <PMID>11456302</PMID>
  </reference>
  <reference>
    <citation>Pozzilli C, Bastianello S, Koudriavtseva T, Gasperini C, Bozzao A, Millefiorini E, Galgani S, Buttinelli C, Perciaccante G, Piazza G, Bozzao L, Fieschi C. Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 1996 Sep;61(3):251-8.</citation>
    <PMID>8795595</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 27, 2005</study_first_submitted>
  <study_first_submitted_qc>December 27, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2005</study_first_posted>
  <last_update_submitted>January 5, 2018</last_update_submitted>
  <last_update_submitted_qc>January 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>S. Andrea Hospital</investigator_affiliation>
    <investigator_full_name>Giovanni Ristori</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Interferon-ß-1b</keyword>
  <keyword>Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

